Figure 1: KAT2A interacts with the α-KGDH complex in the nucleus. Figure 3: α-KGDH-coupled KAT2A regulates H3K79 succinylation and gene expression. Figure 4: H3K79 succinylation by α-KGDH ...

In new research, the team identify a large number of genes that could serve as potential targets for anti-AML treatments and describe how inhibition of one of these genes, KAT2A, destroys AML ...

Auron Therapeutics Inc. has received FDA clearance of its IND application for its oral KAT2A/B degrader AUTX-703 in hematological malignancies. A phase I proof-of-concept trial in acute myeloid ...

“These are the first data to demonstrate AUTX-703’s potent degradation of KAT2A/B promoting cellular differentiation and leading to a significant survival advantage in a primary AML model ...

Using a series of experiments, Auron demonstrated activity with AUTX-703, its oral, potent and selective degrader targeting KAT2A/B in cell lines and patient derived organoid models (PDXO ...

One gene in particular, called KAT2A, when inhibited, disrupted the growth and survival of the leukemia cells without harming surrounding healthy ones. In tests on mice with human leukemia cells ...

The histone acetyltransferase KAT2A, and its paralog KAT2B have been identified as key drivers of tumor cell plasticity in small-cell lung cancer (SCLC). Researchers from Auron Therapeutics Inc. aimed ...

Feb. 04, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today ...

Using a series of experiments, Auron demonstrated activity with AUTX-703, its oral, potent and selective degrader targeting KAT2A/B in cell lines and patient derived organoid models (PDXO) of ...